JP2016512199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512199A5 JP2016512199A5 JP2015561627A JP2015561627A JP2016512199A5 JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5 JP 2015561627 A JP2015561627 A JP 2015561627A JP 2015561627 A JP2015561627 A JP 2015561627A JP 2016512199 A5 JP2016512199 A5 JP 2016512199A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- pharmaceutical composition
- cell surface
- surface molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 241000700562 Myxoma virus Species 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| PCT/US2014/020935 WO2014138314A1 (en) | 2013-03-05 | 2014-03-05 | Oncolytic virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512199A JP2016512199A (ja) | 2016-04-25 |
| JP2016512199A5 true JP2016512199A5 (OSRAM) | 2017-04-06 |
Family
ID=50424733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561627A Pending JP2016512199A (ja) | 2013-03-05 | 2014-03-05 | 腫瘍溶解性ウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160000842A1 (OSRAM) |
| EP (1) | EP2964241A1 (OSRAM) |
| JP (1) | JP2016512199A (OSRAM) |
| CN (1) | CN105407902A (OSRAM) |
| CA (1) | CA2903096A1 (OSRAM) |
| WO (1) | WO2014138314A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| EP3831398A1 (en) | 2013-10-25 | 2021-06-09 | PsiOxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
| US20170281683A1 (en) * | 2014-09-26 | 2017-10-05 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| RU2725799C2 (ru) * | 2015-03-17 | 2020-07-06 | Тилт Байотерапьютикс Ой | Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними |
| US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
| ES2861450T3 (es) * | 2015-07-20 | 2021-10-06 | Virttu Biologics Ltd | Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| CA3004530A1 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| MY193281A (en) | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| JP7312695B2 (ja) * | 2016-07-19 | 2023-07-21 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｓｔａｔ３を標的とする腫瘍溶解性ウイルス |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| JP2019532621A (ja) * | 2016-08-29 | 2019-11-14 | サイオクサス セラピューティクス リミテッド | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| CN118662538A (zh) * | 2017-02-03 | 2024-09-20 | 匹兹堡大学联邦系统高等教育 | 溶瘤病毒疗法 |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| AU2018258049B2 (en) | 2017-04-26 | 2025-03-27 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
| GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
| JP7369127B2 (ja) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体 |
| JP2021508477A (ja) * | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| KR20250114571A (ko) | 2018-01-15 | 2025-07-29 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| BR112020016997A2 (pt) * | 2018-04-13 | 2021-01-19 | F. Hoffmann-La Roche Ag | Moléculas de ligação e de ácido nucleico isolada, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação |
| JP2021525243A (ja) * | 2018-05-21 | 2021-09-24 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法 |
| WO2020017962A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| CA3134140A1 (en) * | 2019-03-28 | 2020-10-01 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Oncolytic myxoma virus expressing fast p14 to treat hematological cancer |
| JP2022530044A (ja) | 2019-04-25 | 2022-06-27 | ディーシープライム・ベスローテン・フェンノートシャップ | 腫瘍ワクチン接種方法 |
| KR102625842B1 (ko) * | 2019-06-27 | 2024-01-17 | 주식회사 바이오녹스 | 안전성 및 항암효과가 개선된 항암바이러스 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| EP3957650A1 (en) * | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| CA3203705A1 (en) | 2021-01-22 | 2022-07-28 | Erik Hans MANTING | Methods of tumor vaccination |
| CN115161293B (zh) * | 2021-04-01 | 2024-11-15 | 南京惟亚德生物医药有限公司 | 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用 |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| KR20080090441A (ko) * | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도 |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US20160015749A1 (en) * | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
-
2014
- 2014-03-05 EP EP14714851.4A patent/EP2964241A1/en not_active Ceased
- 2014-03-05 US US14/770,061 patent/US20160000842A1/en not_active Abandoned
- 2014-03-05 WO PCT/US2014/020935 patent/WO2014138314A1/en not_active Ceased
- 2014-03-05 JP JP2015561627A patent/JP2016512199A/ja active Pending
- 2014-03-05 CA CA2903096A patent/CA2903096A1/en not_active Abandoned
- 2014-03-05 CN CN201480025597.3A patent/CN105407902A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512199A5 (OSRAM) | ||
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Hemminki et al. | Oncolytic viruses for cancer immunotherapy | |
| Schirrmacher et al. | Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy | |
| Fang et al. | NK cell-based immunotherapy for cancer | |
| JP2019519245A5 (OSRAM) | ||
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| JP2018512047A5 (OSRAM) | ||
| JP2019513118A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| JP2020503891A5 (OSRAM) | ||
| JP2018527952A5 (OSRAM) | ||
| RU2017103151A (ru) | Комбинация онколитического вируса с модуляторами иммунологических контрольных точек | |
| JP2019536806A5 (OSRAM) | ||
| JP2008056679A5 (OSRAM) | ||
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| JP2019523221A5 (OSRAM) | ||
| JP2019501670A5 (OSRAM) | ||
| EP3812401A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof | |
| JP2016531927A5 (OSRAM) | ||
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| JP2014532649A5 (OSRAM) | ||
| JP2016028035A5 (OSRAM) | ||
| Rahim et al. | Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine | |
| JP2018023397A5 (OSRAM) |